The Japanese firm Astellas Pharma will apply for planning permission to construct a drug manufacturing facility in Tralee, Co. Kerry, Ireland worth around €330 million ($352 million).
CymaBay announced recently the initiation of its 52-week, placebo-controlled, randomized, phase 3 study — 'Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase (ALP) Levels in subjects with Primary Biliary Cholangitis...
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
A partnership between Banner Health and nference will offer more ‘potent insight generation, offering researchers the option to examine more inclusive data’.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
LighthouseAI, a company that specializes in compliance solutions for the pharmaceutical supply chain, has announced a $2.25 million seed round, led by Healthy Ventures with participation from Bertelsmann Next.
Nathan Johnson has 20 years’ experience in clinical research as an innovator and programmer with expertise in statistical analysis and reporting, SAS programming, standards development, and data management.
Sigma Mostafa is the chief scientific officer of KBI Biopharma, a development and contract manufacturing organization serving the biopharmaceutical industry.
OSP was fortunate enough to have an interesting discussion with Stephen Corson, who is a statistics manager at Phastar, a specialist biometrics CRO headquartered in the UK.
Updated guidelines for risk-based quality management (RBQM) are much more than just for monitoring purposes and can show quality by design concepts, save immeasurable time on manpower and shows there has been a complete mindset shift within the last 15...
Everybody seems to be talking about artificial intelligence at the moment. Some are fascinated, others afraid and a few might worry for their jobs. However, for the pharmaceutical industry, it is said to be completely transforming the landscape.
Phastar is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services and will be providing a presentation and running a workshop to give delegates working...
CluePoints is continuing to invest in artificial intelligence (AI) and machine learning (ML) they say they want to help clients 'extract every drop of potential from the RBQM-driven interrogation of their own datasets'. It says it recognizes...
CDMO Wheeler Bio, Inc. has welcomed Charles River’s flexible biologics testing lab, RightSource, to its Oklahoma City drug substance manufacturing site.
Owlstone Medical has won a contract from the US Department of Defense that will allow it to develop a handheld breath biopsy device for early infectious diseases.
TechBio company, Closed Loop Medicine Ltd, and pharmaceutical company, Pharmanovia have entered into a co-development for precision medicine combination therapeutics.
Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.
As part of a new initiative, the generic manufacturer will boost access to treatments for anxiety and depression across seven new states across the US, potentially reaching more than 650,000 uninsured patients.
Rich Christie is chief medical officer at AiCure LLC. He is a firm believer in digtal biomarkers and the audio and visual biomarkers that can be captured through a front-facing camera. OSP inteviewed him to find about more about the changing landscape...
The company announces plans to reorganize its business to focus on design-and-deployment engagements for on-site implementation of automated cloud labs.
Aerona Clinical is a medium sized pharmaceutical company, represented not only in the United Kingdom, but in Europe, and with a global reach. The company has been operating in this environment in the pharma industry for 15 to 20 years.
The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.
Only a few months after being bought out, the CDMO invests in its capabilities with a facility to support drug-device products and sterile fill-finish.
Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.
A partnership was announced this week (April 11) between non-profit CureDuchenne and health technology company, PicnicHealth that will provide as much data as possible to researchers while helping patients navigate complex medical systems.
OSP spoke to Vladamir Penkrat, head of safety and regulatory and Shuba Rao a senior director at Indegene, a life sciences digital company about a paper they recently published called 'Challenges and Future of PV Compliance' about the direction...
The two French-based companies announced a strategic collaboration at the end of last month (March 2023) that saw Galapagos’ employees working in the research and discovery departments and transferred across to the contract research organization (CRO)....
In its bid to what it says will make participation in clinical trials easier and more sustainable, Greenphire has revealed a patient-powered registry and it has also expanded a deal with Merck.
Progressive supranuclear-palsy (PSP) is a very rare brain disease and until recently, it was almost unheard of. Along with many neurodegenerative diseases, it has a high unmet medical need.
